Sarcopenia, sarcopenic obesity and insulin-resistance by Batsis, J. & Buscemi, S.
12 
Sarcopenia, Sarcopenic Obesity and  
Insulin Resistance 
John A. Batsis1 and Silvio Buscemi2 
1Dartmouth Medical School, Dartmouth-Hitchcock Medical Center 
2University of Palermo, Departmentof Internal Medicine,  
Cardiovascular and Kidney Diseases 
1United States 
2Italy 
1. Introduction 
The number of people greater than 65 years old will increase from 35.9 million in 2003 
(12.4%) to 71.5 million (20%) by the year 2030. Current estimates in the United States 
demonstrate that this population is numbered at 39.6million, representing 12.6% of the 
population, or one in every eight Americans. Women tend to outnumber men and their life 
expectancy is undoubtedly longer. These numbers reflect predominantly the influx of baby 
boomers into this age group (Spillman and Lubitz 2000).  
Since the early part of 1900, the elderly age group has nearly tripled from 4.1% in 1900 to 12.9% 
in 2009, and the number of individuals has increased over thirteen times (from 3.1 to 39.6 
million). The ‘old old’, persons aged >80 are one of the fastest growing segments of the 
population (A Profile of Older Americans 2010). In addition, life expectancy in the elderly has 
been increasing in the past few decades and continues to do so (Lubitz et al. 2003). For 
instance, those reaching the age of 65 years, had a mean life expectancy of 19.9 and 17.2 years, 
respectively, for females and males. Framed alternatively, life expectancy at birth in 2007 was 
77.9 years, approximately 30 years longer than a child born in 1900. Compounded with a 
reduced death rate due to medical advances, patients are living longer than they previously 
were, much of this due to improved survival from cardiovascular and cerebrovascular 
diseases (Ford et al. 2007). Figure #1 demonstrates data on the aging population in the United 
States, and Figure #2 demonstrates estimates from worldwide figures.  
In a report published by the Organisation for Economic Co-operation and Development 
(OECD) in 2007, these trends observed in the United States are paralleled elsewhere. In certain 
countries, specifically Italy and Japan, one out of every five people is aged 65+ (Trends in Severe 
Disability Among Elderly People: Assessing the Evidence in 12 OECD Countries and the Future 
Implications 2007). As in the United States, Table #1 illustrates the proportion of people that 
will be 85+, which is the fastest growing segment of the population. Understandably these are 
worrisome trends as these individuals are, from a public health standpoint, the ones with the 
most number of chronic conditions, disabilities and greatest long-term care needs. It is believed 
that unless there are significant improvements in functional awareness and improvement, this 
group poses the largest burden on existing healthcare resources.  
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Data obtained from the US Census Bureau from the year 2000. www.census.gov 
Fig. 1. Projected Elderly Population of the United States: 2000-2050 
 
 
Fig. 2. Population in OECD Countries of Elderly >65 years old. Proportion of People >65 
years old in a sample of Organisation for Economic Co-operation and Development (OECD) 
countries from 1960 to projects at 2050. Lafortune, G. and G. Balestat (2007), "Trends in 
Severe Disability Among Elderly People: Assessing the Evidence in 12 OECD Countries and 
the Future Implications", OECD Health Working Papers, No. 26, 
http://dx.doi.org/10.1787/217072070078 
 
Country 1960 1980 2000 2030 2050 
Australia 0.4 0.7 1.3 3.2 5.7 
Canada 0.4 0.8 1.3 2.7 5.8 
France 0.7 1.1 2.1 3.8 7.6 
Greece 0.4 0.9 1.3 2.9 4.9 
Italy 0.5 0.8 2.1 4.7 7.9 
Japan 0.2 0.5 1.8 7.4 10.2 
Norway 0.7 1.1 1.9 2.6 4.5 
OECD 0.4 0.7 1.4 3.0 5.2 
Table 1. Proportion of Patients Aged >85 years in OECD Countries. All numbers in the table 
above are percentages Lafortune, G. and G. Balestat (2007), "Trends in Severe Disability 
Among Elderly People: Assessing the Evidence in 12 OECD Countries and the Future 
Implications", OECD Health Working Papers, No. 26, 
http://dx.doi.org/10.1787/217072070078 
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2. Health needs as one gets older 
As patients age, health needs escalate, resulting in disproportionate consumption of health 
care resources (Lakdawalla, Goldman, and Shang 2005). According to a 1995 US Bureau of 
Census publication, approximately 80% of >65 year olds will have a minimum of one 
chronic medical illness, with many suffering multiple. A number of elderly subjects report a 
type of disability, including hearing impairment, visual impairment, cognitive impairment, 
self-care troubles, or needing higher level of care. A number of studies have demonstrated 
the impact of aging on disability. An early study by Vita et al (Vita et al. 1998) studied 1,741 
university alumni, first surveyed in 1962 (mean age 43 years) and then annually in 1986. 
Cumulative disability was determined using a health-assessment questionnaire. Those with 
high health risks at baseline had earlier onset of disability and had a lower follow-up 
disability index. The onset of disability was postponed by more than 5 years in the low-risk 
subject group than those with high risk behaviors. Predictors of subsequent disability 
included smoking, body mass index and exercise patterns in midlife and late-adulthood. 
These authors concluded that although disability is inevitable, the time frame was 
compressed into fewer years at the end of life.  
In one study the number of geriatric conditions was related to dependency in activities of 
daily living (Cigolle et al. 2007). These authors used data from the Health and Retirement 
study survey administered in 2000 on subjects >65 years (n=11,093) residing either in the 
community or in nursing homes, and assessed the number of geriatric syndromes and 
dependency of activities of daily living (ADL)s. Of those >65 years, ~49.9% had at least one 
geriatric syndrome, prevalence rates that were as common as heart disease and diabetes. 
After adjusting for demographic characteristics and chronic diseases, the risk ratio for 
dependence on ADLs were 2.1 [95%CI: 1.9-2.4] for one geriatric condition, 3.6 [3.1-4.1] for 
two conditions, and 6.6 [5.6-7.6] for greater than 3 conditions. This important study 
highlights the similar prevalences of geriatric conditions to chronic diseases in elderly adults 
and their strong association to disability. As the authors note, these are often overlooked in 
the care of older adults. One’s reported disability increases with age. In a study by the 
Administration on Aging in the United States, approximately 56% of persons >80years 
reported a severe disability and 29% reported the need for some type of assistance (A Profile 
of Older Americans 2010). This is of course impairs one self-reported health status and may 
lead to institutionalization.  
3. Muscle changes with aging – Sarcopenia 
As one ages, there are changes in body composition. As patients age, there is a reduction in 
lean mass and a progressive increase in fat mass. This normally occurs after the age of 20-30 
years and can be extensive, involving up to 40% of a population (Baumgartner et al. 1995; 
Flynn et al. 1989; Gallagher et al. 1997; Muller et al. 1996). As is demonstrated in Figure #3, 
maximal fat free mass (muscle mass) is usually reached at about 20 years of age and fat mass 
peaks at the ages between 60 and 70 years (Baumgartner et al. 1995; Gallagher et al. 1997). 
Particularly after the age of 70 years, there is a redistribution of body fat and fat free mass, 
with reductions in peripheral skeletal muscle (Beaufrere and Morio 2000), increases in 
intramuscular and intrahepatic fat, both of which are associated with insulin resistance 
(Cree et al. 2004).  
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Fig. 3. Muscle Mass Changes with Aging. 
Peak muscle mass occurs between the ages of 20 and 30 years, and naturally declines as one 
ages.  
Declining function parallels the concept of sarcopenia. Sarcopenia comes from the Greek 
word, “Sarcos” meaning flesh, and ‘penia’ meaning lack of. This age-related decline in 
lean body mass can affect ambulation, mobility, and functional independence (Morley et 
al. 2001). An analogy often used is the age-related decline in bone mass, where, once it 
reaches a critical level, one’s risk of fracture is increased. Sarcopenia can be 
conceptualized on the spectrum of frailty and disability and has been shown to be 
increasingly prevalent with age. More recently, the concept of declining strength has 
been incorporated into the definition, although, a widely accepted definition of 
sarcopenia has yet to be established (Cruz-Jentoft et al. 2010)). Sarcopenia indeed can be 
considered a geriatric syndrome. These are common, complex and costly entities of 
impaired health in elderly individuals which involve multiple systems, have a myriad of 
interactions, and have varied phenotypes. Falls, urinary incontinence and delirium are 
but some examples of such. Sarcopenia has also been associated with malnutrition and 
diminished physical function, both of which are associated with geriatric functional 
decline and mortality. The loss of muscle mass during the aging process is important 
clinically as it reduces strength and exercise capacity, both which are needed to perform 
one’s activity of daily living. It is hypothesized that subjects reach a given threshold at 
which impairment in function occurs. Absolute loss of muscle mass leads to reduced 
muscle function and hence physical performance measures are increasingly being used 
in the definition and identification of sarcopenia. There are a number of definitions 
outlined in the literature making standardization, particularly in clinical practice, rather 
difficult (Baumgartner et al. 1998; Bouchard, Dionne, and Brochu 2009; Davison et al. 
2002; Zoico et al. 2004) . Prevalence rates can vary dramatically and is the subject of 
current investigation. This syndrome has a number of risk factors, a number that are 
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modifiable over the course of one’s life span, but can have profound impact on one’s 
overall state of health and quality of life.  
The trajectory of one’s muscle loss can be altered by physical exercise and/or the 
environment. Muscle mass develops up to the age of 20 and 30 years, and is relatively 
maintained throughout adult life. As one ages, muscle mass decreases and one reaches a 
threshold whereby low muscle mass will inevitably lead to disability and future 
complications (Sayer et al. 2008). 
Assessing sarcopenia has been a challenge in the research literature. There are a number 
of definitions that have been proposed, yet they have been developed on different 
populations and ethnicities, factors which are known to affect body composition. 
Additionally, muscle quality and strength have yet to be incorporated into such 
definitions. Recently, there was a European consensus on the definition and diagnosis on 
Sarcopenia (Cruz-Jentoft et al. 2011). This taskforce suggested the use of both low muscle 
mass and low muscle function (strength or performance) for the diagnosis of sarcopenia. 
The rationale for using these criteria include that muscle mass and muscle strength are not 
directly correlated to each other (Goodpaster et al. 2006; Janssen et al. 2004). DEXA 
scanning is unique in that it not only allows ascertainment of muscle mass but can be used 
concurrently to assess bone density as well. Bioelectrical impedance on the other hand is 
inexpensive, and easily reproducible with prediction equations available to calculate 
various measures of body composition (Chumlea et al. 2002) and has been considered as a 
portable alternative to DEXA. Body water can affect these results, though, and elders’ 
changes in body composition, both in health and disease, may affect such estimates. 
Unfortunately, the relative availability and cost of DEXA in particular can be prohibitively 
expensive, not portable, and would be impractical to use for routine use in an office 
setting (Chien, Kuo, and Wu 2010). Other measures, including grip strength, knee 
strength, or gait speed have been proposed but no studies have validated such measures.  
Figure #4 (Cruz-Jentoft et al. 2011) illustrates the proposed mechanisms of sarcopenia. These 
vary over one’s lifespan and are impacted by each other, with interactions that are poorly 
understood.  
4. Aging and obesity 
Along with the rise in the number of elderly patients, the number of patients diagnosed 
with overweight and obesity are increasing. Obesity is defined by the World Health 
Organization (WHO) as a body mass index (BMI) greater than or equal to over 30kg/m2, 
calculated as the body weight in kilograms divided by the height in meters squared 
(Quetelet 1871). Little attention has been given to the obese elder, largely due to a paucity 
of studies including elderly (>65 years old) patients. Yet, current estimates, specifically in 
the United States population, indicate that the prevalence of obesity continues to rise, and 
exceeds 35% of the general population, a trend that is also observed in elderly subjects. 
The prevalence of obesity has increased almost three-fold from 1960-2008, and continues 
to rise at a frightening rate (Flegal et al. 2011). Latest estimates illustrate by using body 
mass index as a surrogate for obesity estimates, that 33.6% of women and 37.1% of males 
are classified as having obesity over the age of 60years (Flegal et al. 2010). These numbers 
are remarkably higher than estimates in 1999 whereby 31.8% of males were obese, yet 
prevalence estimates seem to be similar in females. However, trends demonstrate rises in 
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prevalence rates, in particular subjects with morbid obesity (BMI >40kg/m2). Figure #5 
illustrates these trends. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Mechanisms of Sarcopenia. The Sarcopenia taskforce did conclude the importance of 
identifying such mechanisms to better understand the underlying pathophysiology, and to 
allow the identifications of interventions these targets.  
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Obesity is associated with an increased number of medical conditions and complications, 
and is a recognized independent cardiovascular risk factor. Obesity is associated with an 
increased risk of both physical and cognitive disability (Beydoun, Beydoun, and Wang 2008; 
Jensen 2005). Houston et al used data from the Health, Aging and Body Composition Study 
in looking the association between overweight and/or obesity in young, middle, and late 
adulthood and its cumulative effect on incident mobility limitation in 2,845 community 
dwelling US adults (Houston et al. 2009). The authors identified mobility limitations as 
difficulty walking ¼ mile or climbing 10 steps over a 7-year of follow-up. Men and women 
who were overweight or obese at all three time points had increased risk of mobility 
limitations compared to normal weights (HR 1.61 [1.25-2.06], and 2.85 [2.15-3.78]. There 
appeared to be a graded response (P<0.001) on risk of mobility limitations on the cumulative 
effect of obesity in men and women. Earlier onset of obesity in life contributed to increased 
mobility limitations of old age (Houston et al. 2009). This is also observed in Figure #6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Obesity in the United States, 1960-2008.Trends in the obesity epidemic in the United 
States in both males and females over the age of 60 years. In males, the trajectory of multiple 
epidemiological surveys is that of an increase. In females, there was an initial drop, but 
subsequent, yet steady increase 
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Caption: Hazard ratios and 95% confidence intervals for incident mobility limitation among Men (A) 
and women (B) by history of overweight or obesity (BMI >25kg/m2), the Health, Aging and Body 
Composition Study, 7 years of followup. Models were adjusted for age, race, field center, education, 
smoking status, alcohol consumption, and physical activity at study baseline. (Houston et al. 2009)  
Fig. 6. Mobility Limitations and Body Size 
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A recent study using NHANES data demonstrated a J or U-shaped association between 
overweight/obesity and years of life lost, with the study authors concluding that obesity 
appears to decrease life expectancy (Figure #7) (Flegal et al. 2005). In addition, recent meta-
analyses using body mass index as a surrogate for obesity have demonstrated that 
regardless of age, mortality is increased in patients with a BMI <22kg/m2 and those who are 
morbidly obese (BMI>35kg/m2) [Figure #8] (Whitlock et al. 2009). Continued debate in the 
literature with regard to associations of mortality with BMIs between 25 and 35 continue 
and will not be reviewed here. Obesity has also been demonstrated to be associated with 
disability, lower quality of life, and increased resource utilization, particularly in elderly 
subjects (Guralnik, Fried, and Salive 1996). Obesity is associated with nursing home 
admissions and increasing one’s risk to be homebound (Jensen et al. 2006; Valiyeva et al. 
2006; Zizza et al. 2002). These issues all create a worrisome public health concern in that, in 
one study, 9% of all total excess healthcare costs may be attributable to overweight or 
obesity (Finkelstein, Fiebelkorn, and Wang 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Caption: BMI indicates body mass index, measured as weight in kilograms divided by the square of 
height in meters. The reference category with relative risk 1.0 is BMI 18 to <25. Error bars indicate 95% 
confidence intervals. Copryight © American medical Association, JAMA 2005;293:1861-1867, All Rights 
Reserved. (Flegal et al. 2005) 
Fig. 7. Relative Risks of Mortality by Body Mass Index Category by Epidemiological Survey 
Data 
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Fig. 8. All-cause mortality vs. Body Mass Index. 
These studies demonatrate J-shaped curves in all age groups, in the range 15-50kg/m2 by 
age at risks (excluding the first 5 years of followup) (Whitlock et al. 2009) 
5. Sarcopenic obesity – A subset of sarcopenia and obesity 
Often times, we consider sarcopenia in the context of weight loss and cachexia; but sarcopenia 
can occur with obesity. The impact of obesity on sarcopenia continues to be a subject of 
investigation and emerging as a public health problem. In subjects who gain weight, there is 
proportionally an increase in fat mass as compared to lean mass. As described above, both 
entities lead to disability and the synergistic effects lead to worsening disability. These subjects 
can also be considered ‘fat frail’ who suffer from increased weakness from sarcopenia and the 
requirement to carry additional weight from obesity (Launer et al. 1994).  
Common inflammatory pathways have linked sarcopenia and obesity yet the interplay 
between these two entities is poorly understood. One author hypothesized that both 
sarcopenia and obesity are similar behaviorally and biologically (Roubenoff 2000). One of 
the most trophic effects on muscle is physical activity, which normally falls as people age. 
Concurrently, there is a positive energy balance and weight gain, predominantly fat in 
nature. Additionally, this loss of fat-free mass (muscle) lowers the amount of tissues that can 
respond to insulin targeting, thereby promoting insulin resistance, metabolic syndrome and 
obesity (Reaven 1988). Muscle and fat are both metabolically active, the latter producing 
TNF-a, IL-6 and adipokines all of which have a direct catabolic effect on the former, and 
promote insulin resistance. Leptin and low adiponectin concentrations have been found to 
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negatively impact muscle mass and lead to a decline in muscle quality (Hamrick et al. 2010). 
On a biological level, macrophages in adipocytes or in adipose tissue, produce such 
proinflammatory cytokines (Fantuzzi 2005) which can upregulate the inflammatory 
response. Cesari et al. evaluated the relationship between body-composition measures and 
inflammatory markers, using data from the Trial of Angiotensin Converting Enzyme 
Inhibition and Novel Cardiovascular Risk Factors study (Cesari et al. 2005). These authors 
demonstrated the positive association of CRP and IL-6 with BMI (p=0.03 and p<0.001) and 
total fat mass (<0.001 and <0.001), and inverse association with fat-adjusted appendicular 
lean mass (p<0.002 and p=0.02). Using data from the INChianti study, global and central 
obesity directly affect inflammation, negatively affects muscle strength and can contribute to 
the development and progression of sarcopenic obesity (Schrager et al. 2007).  
This cycle continues until the development of disability and medical illnesses. Furthermore, 
compounding the decline in neuronal and hormonal signals that occur with aging, 
malnutrition, and loss of a-motor units and changes in gene expression, further increase the 
risk of this entity in occurring (Doherty et al. 1993; Marcell 2003; Morley et al. 2001). This 
pro-inflammatory state leads to a perpetuating cycle of reduced muscle strength among 
obese subjects inevitably further contributing to functional decline. The aging process also 
itself leads to elevated IL-6 levels, TNF-α and CRP as well. While a number of chronic 
medical conditions prevalent in elders, including cancer, COPD and heart failure are 
associated with elevated pro-inflammatory levels and can lead to loss of muscle mass, the 
process of age-related sarcopenia is a natural phenomenon and differs from such.  
Baumgartner et al. defined sarcopenic obesity as a muscle mass index less than two standard 
deviations below the sex-specific reference for a young healthy population (Baumgartner 
2000). Alternative definitions have been used by other authors (Bouchard, Dionne, and Brochu 
2009; Davison et al. 2002; Zoico et al. 2004), yet a harmonious definition has yet to be solidified 
at this time. More recently, the incorporation of muscle quality into these definitions has been 
proposed (Cruz-Jentoft et al. 2010). The debate is outside the scope of this chapter.  
A number of studies have outlined the differences between those with and without 
sarcopenia or obesity. In one of the pivotal studies, 52 subjects matched obese elderly, non-
obese frail, and non-obese, non-frail were evaluated on objective measures of functional 
status and health-related quality of life and differences in body composition (Villareal et al. 
2004). They discovered that obese and non-obese frail groups had lower and similar scores 
in physical function, functional status and impairments in strength and walking speed. They 
concluded that physical frailty in obese elders was associated with lower fat free mass (lean 
mass), poor muscle quality and worsening quality of life. 
One of the more pivotal studies by Baumgartner’s group demonstrated the combined effect 
of obesity and muscle mass or strength on physical functioning or disability (Baumgartner 
2000). Baumgartner’s group examined the impact of sarcopenic obesity and incident 
instrumental ADL disability in the New Mexico elder health survey and New Mexico aging 
process study (Baumgartner et al. ). This study ascertained ADLs in patients longitudinally 
and assigned points (0-2) depending on whether someone could not perform an 
instrumental activities of daily living, could do it with difficulty, or could do it 
independently. Their primary outcome was time to a drop in ADL, defined as a drop in 2 
points. As can be seen in the Figure #9 below, only those with sarcopenic obesity had a 
markedly shorter time to drop in ADLs. The other three groups were no different from each 
other (sarcopenic non-obese, obese non-sarcopenic, and non-obese non-sarcopenic).  
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SO – sarcopenic obesity; S – sarcopenia; O – obesity; NS – non-sarcopenic; NO – non-obese 
Fig. 9. Incident Disabilty over Time.  
The data demonstrate that subjects with Sarcopenic Obesity have worsened disability, than 
subjects with sarcopenia alone, obesity alone, or neither sarcopenia nor 
obesity(Baumgartner et al. 2004).  
Other cross-sectional studies have demonstrated conflicting results based on NHANES III 
(Davison et al. 2002) and a sample of elder females in Verona (Zoico et al. 2004). Davison’s 
study looked at 1,526 females and 1,391 males who were 70 years and older. These authors 
observed that women in the highest quintile for percent body fat were twice as likely to 
report functional limitations than in the other comparison groups, and weaker but similar 
relationships were observed in men. Low muscle mass and sarcopenia with obesity, in this 
study were not associated with additional limitations. In Zoico’s cross-sectional study of 167 
females, aged 67-78, those in the highest quintile of body fat demonstrated a significantly 
higher prevalence of functional limitation, but 40% of sarcopenic elderly women and 50% of 
elderly women with high body fat and normal muscle mass were functionally limited 
(Figure #10). Functional limitation increased in those with a higher degree of sarcopenia. 
They demonstrated that isometric leg strength was significantly lower in subjects with 
sarcopenia and sarcopenic obesity. These two studies used the same categorization to define 
these entities. It was felt that using muscle mass instead of a functional measure such as 
strength as an indicator of sarcopenia may have explained the lack of results. 
 
 
Fig. 10. Self-Reported Functional Limitations 
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There were no differences between subjects in this cohort on self-reported functional 
limitations with regard to body composition measures (Zoico et al. 2004). 
There are other studies that have demonstrated the relationship between sarcopenic 
obesity and higher degrees of functional limitations. Stenholm et al (Stenholm et al. 2008) 
examined the association between different obesity indicators and walking limitations in 
examining the role of C-reactive protein and handgrip strength. This cross-sectional study 
of a Finnish population looked at subjects >55 years, and demonstrated that the highest 
two quartiles of body fat percent and C-reactive protein and the lowest two quartiles of 
handgrip strength were significantly associated with greater risk of walking limitations 
after adjusting for chronic diseases and other pertinent co-variates. The prevalence of 
walking limitations were higher in persons who had high fat and low handgrip (61%) 
than in those with low fat and high handgrip (7%). Their results are better observed in the 
figure below: 
 
 
Fig. 11. Walking Limitations, C-reactive Protein and Handgrip Strength. 
Age- and sex-adjusted prevalence of walking limitations according to body fat percentage 
levels according to C-reactive protein (CRP) and handgrip strength. Low, medium and high 
levels of body fat percentage, CRP and handgrip strength were defined by recoding 
quartiles of each variable in to three categories by combining quartiles II and III. Numbers 
inside the bars indicate the number of subjects in each category (Stenholm et al. 2008). 
Finally, Cesari’s group (Cesari et al. 2009), using the InCHIANTI study, analyzed data from 
934 participants aged 65 years and older with at least 6 years of follow-up. In unadjusted 
analyzes, muscle density (HR 0.78 [0.69-0.88]), muscle area (HR 0.75 [0.66-0.86]) and fat area 
(HR 0.82 [0.73-0.92) were associated with mortality. However, adjusting for confounders, 
these associations were no longer significant. Walking speed was associated with mortality 
risk (HR 0.73 [0.60-0.88]). The relationship with mortality, though, has been examined by 
other others. Rantanen (Rantanen et al. 2000). Those who were overweight in the lowest grip 
strength tertile had 1.4 times higher mortality risk compared to normal weight persons in 
the highest grip strength. Muscle strength has been previously examined as a predictor of 
mortality (Gale et al. 2007; Newman et al. 2006; Rantanen et al. 2003) and that of obesity has 
been fully described previously.  
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6. Aging, sarcopenia, insulin and insulin resistance 
There are hormonal changes linking age-related decline in muscle strength and mass, 
which include insulin, growth hormone, and catecholamines as a few examples. On a 
cellular level, animal studies have demonstrated a relationship between obesity-related 
insulin resistance and insulin receptor signaling pathway. A low grade inflammation 
often is present in most obese patients which is a result of chronic activation of the innate 
immune system, leading to insulin resistance, impaired fasting glucose and diabetes. The 
involvement of cytokines and inflammation in obesity in relation to glucose metabolism 
continues to be controversial. Both IL-6 and TNF- alter insulin sensitivity by impacting 
given steps in the insulin signaling pathway. In animal models, resistin induces insulin 
resistance, but whether this occurs in humans is unclear. Subjects with obesity-related 
insulin resistance, type 2 diabetes and coronary heart disease have low levels of 
adiponectin. This hormone is known to inhibit liver gluconeogenesis and can promote 
fatty acid oxidation in skeletal muscle. These cytokines also are known to impact NF-kB 
and JNK systems (Zamboni et al. 2007).  
With aging, muscle can be infiltrated with fat, and this may eventually perpetuate 
insulin resistance. In a large study of 2,964 elderly subjects with a mean age of 73.6 years, 
despite similar amounts of subcutaneous thigh fat, intermuscular fat was higher in 
subjects with type 2 diabetes and impaired glucose tolerance than in subjects with 
normal glucose tolerance (p<0.001) (Goodpaster et al. 2003). As expected higher rates of 
intermuscular fat and visceral abdominal fat were associated with higher fasting insulin 
levels. This study concluded that elderly men and women with normal body weight may 
be at risk for metabolic abnormalities, including type 2 diabetes if they possess an 
inordinate amount of muscle fat or visceral abdominal fat. A smaller study by the same 
group elucidated whether thigh fat was a determinant of insulin resistance. They 
compared a small number of subjects and confirmed that muscle composition reflected 
increased fat content was associated with insulin resistance (Goodpaster, Thaete, and 
Kelley 2000). 
Furthermore, insulin is well known to be an anabolic hormone which may have a 
pleiotrophic effect on muscle tissue and protein metabolism. Lower protein synthesis 
and higher insulin levels occur in elderly subjects compared to younger subjects after 
food intake. Previous studies have shown that subjects with insulin resistance can 
negatively predict muscle strength, often seen in elderly subjects with diabetes. The 
correlation between insulin resistance and muscle strength is quite poor and accelerates 
the loss of leg muscle strength and quality. In a pilot study examining this relationship 
examined the homeostasis model assessment (HOMA-IR) in type 2 diabetes, 
demonstrated that knee extension, adjusted for body weight was significantly correlated 
with HOMA-IR in both sexes and that this relationship persisted as an independent 
determinant in a stepwise regression model (Nomura et al. 2007). In another study, the 
degree of insulin resistance was evaluated using HOMA-IR and muscle strength using 
handgrip strength. BMI-adjusted handgrip strength correlated positively with physical 
activity, muscle area, and muscle density (Abbatecola et al. 2005). Physical activity has a 
positive effect on muscle mass and quality specifically with resistance training 
(Goodpaster and Brown 2005). This latter activity is also known to improve insulin 
sensitivity and glycemic control.  
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Fig. 12. Possible Mechanisms linking Ageing, Obesity, Sarcopenia and Insulin resistance 
(Zamboni et al. 2008) 
7. Growth hormone and insulin-like growth factor 1 
Additional contributors to sarcopenia include insulin-like growth factor-1 (IGF-1) and 
growth hormone (GH), both of which decline with age. Growth hormone is associated with 
low fat mass, increased lean body mass and ideal metabolic profile, while IGF-1 can increase 
protein synthesis in existing muscles. One study partially described the relationship of the 
hypothalamic pituitary axis in subjects with sarcopenia and sarcopenic obesity. Using 
DEXA, they ascertained 45 subjects with varying degrees of adiposity and lean mass and 
measured pituitary function (Waters et al. 2008). They demonstrated that appendicular 
skeletal muscle mass was independently and negatively correlated with leptin in all groups, 
even after adjusting for body fat, and that subjects with sarcopenic obesity had lowered and 
blunted GH responses. Low levels of this anabolic hormone has been proposed to be 
positively associated with low muscle strength (Ceda et al. 2005). Using data from the 
Longitudinal Ageing Study Amsterdam (LASA), among subjects aged 65-88 years, serum 
testosterone levels were positively associated with muscle strength and physical 
performance (Schaap et al. 2005). With respect to IGF-1 levels, physiologically one would 
expect that the age-associated decline in IGF-1 levels would be associated with poorer 
muscle strength and mobility. Data from 617 women from Women’s Health and Aging 
Study were examined and demonstrated a positive association between IGF-1 levels and 
knee extensor strength (p=0.004) and walking speed (P<0.001). A decline in IGF-1 levels was 
associated with difficulty self-reported mobility tasks. It is hypothesized that the aging 
muscle loses the capability of secreting GH and the responsiveness to IGF-1 is also likely 
attenuated. Evidence suggests that exercise can reverse the latter. These may be molecular 
targets in the future to promote muscle building and prevent sarcopenia.  
8. Diabetes and geriatric syndromes 
Diabetes is associated with an increased incidence of many geriatric syndromes. Many 
studies have demonstrated the impact of diabetes on functional impairment, including 
inability to ambulate and perform instrumental ADLs (Volpato et al. 2002; Gregg et al. 2002). 
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Diabetes itself, on a microvascular level can lead to functional impairment, but notably, 
complications of diabetes have also been implicated. Diabetes has been implicated in fall 
risk (Volpato et al. 2005), fractures (Schwartz et al. 2001), urinary incontinence (Ebbesen et 
al. 2007) and depression (Anderson et al. 2001). 
9. Diabetes and sarcopenia 
There are a number of similarities between diabetes and sarcopenia. It is known that persons 
with diabetes have an accelerated aging process leading to disability and frailty. Diabetes is 
known to lead to each of the components of the operationalized definition of frailty and 
insulin resistance appears to be a core factor in this pathophysiology (Morley 2008). In the 
Health, Aging and Body Composition study, type 2 diabetes was associated with lower 
skeletal muscle strength and quality, as well as excessive skeletal muscle mass loss (Park et al. 
2006; Park et al. 2009). Loss of muscle mass has also been associated with type 2 diabetes in 
elderly subjects. Low grip strength as a surrogate for sarcopenia is associated with features of 
metabolic syndrome as well, post-prandial glucose levels and HOMA index/ insulin-
resistance. It is believed that hyperglycemia directly impairs skeletal muscle contractility and 
force (Sayer et al. 2005) ; whether this is due to excessive toxicity of sugar alcohols on muscles 
remains elusive at this time. Other hypotheses include the accumulation of lipids which may 
affect insulin signaling (Janssen and Ross 2005; Furler et al. 2001; Shulman 2000), impaired rate 
of synthesis of muscular proteins, seen in both ageing and insulin resistance (Nair 2005; 
Rasmussen et al. 2006). Diabetics are at high risk for sarcopenia as there is a 1.5-2.0 fold 
increased rate of skeletal muscle mass and strength loss (Park et al. 2007). There are a number 
of similarities between metabolic syndrome and insulin resistance and one study by Sayer 
examined the relationship between these entities and sarcopenia (Sayer et al. 2007). Their 
findings suggested that impaired grip strength was associated, not only with individual 
constructs of the metabolic syndrome but also the composite definition itself. Although the 
authors acknowledge that further investigation is required to understand the underlying 
mechanisms, the potential for using grip strength and interventions tested thereof to improve 
muscle strength, could also potentially improve insulin resistance. The following figure 
(Figure #13) demonstrates some of the potentiating cellular mechanisms observed in diabetes. 
There are a number of emerging studies observing the relationship between sarcopenia, 
obesity, sarcopenic obesity and diabetes. The Korean Sarcopenic Obesity Study examined 
the prevalence of sarcopenia in Korean subjects with and without type 2 diabetes (Kim et al. 
2000). The study included 810 subjects, of which 414 had diabetes and 396 were controls, 
and demonstrated that the prevalence of sarcopenia was 15.7% and 6.9% in subjects with 
and without diabetes. Skeletal muscle index (muscle mass adjusted for height squared), as a 
measure of sarcopenia, was significantly lower in patients with diabetes compared to 
subjects without diabetes. In their multiple logistic regression model, type 2 diabetes was 
independently associated with sarcopenia (OR 3.06 [1.42-6.6.62)] than subjects without 
diabetes after adjusting for age, sex, BMI, smoking, alcohol consumption, physical activity, 
medications, blood pressure and lipid profiles. Quite interestingly, though, the prevalence 
of type 2 diabetes was highest in Mexican Americans using NHANES III data with the 
lowest prevalence of obesity and sarcopenia, while Whites had the highest prevalence of 
sarcopenic obesity (Castaneda and Janssen 2005). This study challenges whether there 
indeed is a relationship between sarcopenia and obesity. Whether ethnicities need to be 
accounted for due to differences in body composition is a matter of further investigation.  
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↓, decreased, ↑ increased; KT, active human protein kinase (protein kinase-B); FOXO, forkhead protein; 
MURF, muscle ring finger protein; P13K, phosphatidyl inositol-3-kinase (Morley 2008).  
Fig. 13. Biochemical Changes in Muscle in Diabetes 
In other population, specifically, dialysis subjects, diabetes is thought to be a risk factor for 
losing lean mass (Pupim et al. 2005). Muscle mass, particularly in dialysis patients, are 
known to decline continuously and hence this study suggested that controlling a risk factor 
for incipient sarcopenia (diabetes), would reduce this declining process. Many of the 
changes suggested, in one editorial, were due to systemic inflammatory cytokines 
previously described, often which are implicated in diabetes and insulin resistance (Kaysen 
2005). This was echoed in another small study looking at changes in inflammatory cytokines 
implicated in losing lean mass (Pedersen et al. 2003). 
Subjects with diabetes are at higher risk of developing peripheral neuropathy, which leads 
to a decrease in one’s motor end plates. This entity is important in maintaining muscle 
homeostasis and coordination of muscle contraction, therefore their loss can perpetuate and 
accelerate age-related decline in muscle mass. Diabetics also have impaired levels of growth 
hormone and pro-inflammatory cytokines. Additionally, the microvascular damage from 
hypoxia not only affects nerves, renal glomeruli and optic nerves, but also can lead to 
muscle hypoxia. Macrovascularly, atherosclerosis can lead to diminished peripheral blood 
flow to leg muscles leading to impaired strength. Other cellular entities are implicated, as 
well as other endocrine changes as illustrated in the figure below. Undoubtedly there is a 
relationship between the underlying pathophysiology of sarcopenia, insulin resistance and 
diabetes. 
10. Conclusion 
A number of studies are increasingly confirming the relationship between sarcopenia and 
reduced functional activities and disability. Sarcopenia and obesity are often thought as a 
preludes to frailty, known to adversely predict hospitalizations, morbidity, 
institutionalization and mortality (Figure #14). Reduced physical activity and a sedentary 
lifestyle are important risk factors for developing sarcopenia, which subsequently leads to 
physical disability and reduced physical performance (Figure #15). More importantly, those 
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with elevated fat mass with sarcopenia are at even high risk. The relationship between 
sarcopenia, sarcopenic obesity and insulin resistance requires further investigation. The 
clinical implications are not insignificance in that globally, sedentary lifestyles are becoming 
the norm and the potential implications on utilization are not significant.  
 
 
Fig. 14. Possible Consequence of sarcopenic obesity in the Elderly (Zamboni et al. 2008) 
 
 
Fig. 15. Body Composition Changes Leading to Sarcopenic Obesity (Jarosz and Bellar 2009) 
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11. Abbreviations 
ADL – Activities of Daily Living 
BMI – body mass index 
BIA – bioelectrical impedance analysis;  
DEXA – Dual Energy X-Ray Absorptiometry  
HOMA – homeostatic model assessment 
HOMA-IR – homeostasis model of assessment – insulin resistance 
OECD – Organisation of Economic Cooperation and Development 
US – United States 
TNF- – tumor necrosis factor α 
IL-6 – interleukine 6 
GH – growth hormone 
NK-kB - nuclear factor-kappa B 
JNK - Jun N-terminal kinases 
IGF-1 - insuline-like growth factor 1 
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